9-position Substituted Patents (Class 514/180)
  • Publication number: 20110281834
    Abstract: The present invention provides pharmaceutical formulations suitable for iontophoresis that provide enhanced iontophoretic delivery of a corticosteroid to the skin.
    Type: Application
    Filed: November 10, 2009
    Publication date: November 17, 2011
    Inventors: Phillip M. Friden, Hyun Kim, Bireswar Chakraborty
  • Publication number: 20110274738
    Abstract: Provided herein are methods for functionalizing a polymer for forming a coating and coatings and devices formed thereof or for functionalizing a coating or device surface including an polymer.
    Type: Application
    Filed: July 19, 2011
    Publication date: November 10, 2011
    Inventors: Stephen Dirk Pacetti, Syed Faiyaz Ahmed Hossainy
  • Publication number: 20110268781
    Abstract: The present invention relates to materials having therapeutic compositions releasably contained within the materials. The materials are configured to release therapeutic compositions at a desired rate. The present invention also relates to devices incorporating the materials.
    Type: Application
    Filed: May 9, 2011
    Publication date: November 3, 2011
    Applicant: Gore Enterprise Holdings, Inc.
    Inventors: Robert L. Cleek, Edward H. Cully, Jeffrey B. Duncan, Theresa A. Holland, Thomas R. McDaniel, Christine M. Scotti
  • Publication number: 20110263551
    Abstract: A method is provided for treating swimmer's ear and other types of otitis externa. The method comprises (a) diagnosing an instance of swimmer's ear in a patient; and (b) applying to the meatal tissues of the external ear of the patient, in a single application, a volume of a pharmaceutical composition preferably within the range of about 0.1 ml to about 1.5 ml. The pharmaceutical composition comprises a corticosteroid disposed in a viscous medium, and preferably also includes an antifungal agent. The corticosteroid is preferably betamethasone or a betamethasone derivative, and the concentration of the corticosteroid is preferably within the range of about 0.45 mg to about 0.9 mg per gram of the pharmaceutical composition.
    Type: Application
    Filed: June 8, 2011
    Publication date: October 27, 2011
    Inventor: Patrick Slater
  • Publication number: 20110262547
    Abstract: Carrier particles in which at least 60% of the surface is coated with magnesium stearate are useful for preparing dry powder formulations for inhalation.
    Type: Application
    Filed: April 1, 2011
    Publication date: October 27, 2011
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: Rossella Musa, Daniela Cocconi, Alain Chamayou, Laurence Galet
  • Publication number: 20110251142
    Abstract: Use of triterpene and anthraquinone glycosides, as substances exerting hydragogue activity on mucosa of upper respiratory apparatus, for the treatment of the effects resulting from the upper respiratory tract diseases. The present invention concerns the use of triterpene and anthraquinone glycosides, as substances exerting hydragogue activity on mucosa of upper respiratory apparatus, for the treatment of the effects resulting from the upper respiratory tract diseases as for example, sinusitis, both acute or chronic, rhinosinusitis, rhinitis.
    Type: Application
    Filed: March 18, 2011
    Publication date: October 13, 2011
    Inventor: Sandro Soriano
  • Patent number: 8034366
    Abstract: The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: October 11, 2011
    Assignee: Allergan, Inc.
    Inventors: Jane-Guo Shiah, Rahul Bhagat, Wendy M. Blanda, Thierry Nivaggioli, Lin Peng, David Chou, David A. Weber
  • Patent number: 8034370
    Abstract: The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: October 11, 2011
    Assignee: Allergan, Inc.
    Inventors: Jane-Guo Shiah, Rahul Bhagat, Wendy M. Blanda, Thierry Nivaggioli, Lin Peng, David Chou, David A. Weber
  • Publication number: 20110244017
    Abstract: The present invention provides an absorbable coating for an implantable device and the methods of making and using the same.
    Type: Application
    Filed: March 31, 2010
    Publication date: October 6, 2011
    Applicant: ABBOTT CARDIOVASCULAR SYSTEMS INC.
    Inventors: Lothar W. Kleiner, Syed F.A. Hossainy, Mikael Trollsas, Stephen D. Pacetti
  • Publication number: 20110245217
    Abstract: The present invention relates to asthma. Particularly, the present invention relates to clinical screening, diagnosis, prognosis, therapy and prophylaxis, as well as for drug screening and drug development for the treatment of asthma. The present invention relates to a new paradigm in diagnosing, screening, and treating asthma by affecting airway epithelial synchronization.
    Type: Application
    Filed: April 6, 2011
    Publication date: October 6, 2011
    Applicant: THE CHILDREN'S RESEARCH INSTITUTE
    Inventors: Robert J. FREISHTAT, Eric P. Hoffman
  • Publication number: 20110244043
    Abstract: A controlled releasing composition comprising a plurality of microparticles and a matrix as well as the preparation method thereof is disclosed. The plurality of microparticles comprise a first material and the matrix comprises a second material. The melting temperature of the first material is higher than the melting temperature of the second material.
    Type: Application
    Filed: December 10, 2009
    Publication date: October 6, 2011
    Inventors: Jianjian Xu, Shiliang Wang, Manzhi Ding
  • Patent number: 8030296
    Abstract: There is provided a compound of Formula I wherein X is a ring system; R1 is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group; R2 is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group; wherein when X is a steroidal structure and both of R1 and R2 are sulphamate groups, the steroidal ring system (X) represents an oestrogen; and wherein said compound is capable of inhibiting steroid sulphatase (STS) activity and/or is capable of acting as a modulator of cell cycling and/or as a modulator of apoptosis and/or as a modulator of cell growth.
    Type: Grant
    Filed: March 3, 2006
    Date of Patent: October 4, 2011
    Assignee: Sterix Limited
    Inventors: Barry Victor Lloyd Potter, Michael John Reed, Lok Wai Lawrence Woo, Hatem Hejaz, Bertrand Leblond, Matthew Paul Leese, Atul Purohit
  • Publication number: 20110238016
    Abstract: A drug delivery device may include a base to be percutaneously affixable in an attachment zone of a synovial joint and a sustained-release drug carrier coupled to the base. The drug delivery device may also include an access device to provide access to the attachment zone. The attachment zone may comprise a non-articulating portion of a bone and/or cartilage with the synovial joint and the drug carrier may elute the drug into the synovial fluid sufficient to sustain a therapeutically effective concentration of the drug in the synovial fluid for at least 8 hours.
    Type: Application
    Filed: June 8, 2011
    Publication date: September 29, 2011
    Applicant: Hospital for Special Surgery
    Inventors: Robert N. HOTCHKISS, John A. Koski
  • Publication number: 20110237563
    Abstract: The present invention related to the administration of bioactive agents via oral fast dispersing/dissolving drug delivery systems for treating illnesses of patient with critical buccal condition, leading to difficulties in swallowing oral medicine forms and thus difficulties in treating said illnesses. Particularly, the present invention discloses the administration of bioactive agents via oral fast dispersing/dissolving drug delivery systems for treating illnesses of patient with dysphagia and/or odynophagia and/or aspiration risk. Another aspect of the present invention is the administration of bioactive agents via oral fast dispersing/dissolving drug delivery systems for the treatment of dysphagia and/or odynophagia and/or aspiration risk.
    Type: Application
    Filed: March 23, 2010
    Publication date: September 29, 2011
    Inventor: Dominique Costantini
  • Patent number: 8026229
    Abstract: The present invention relates to the use of 2-alkoxyestrogen sulfamates of general formula I wherein R1 and R2 independently represent H, methyl, C1-C4 acyl, benzoyl R3 represents C1-C4 alkyl or a group of formula CnFmHo, wherein n=1, 2, 3, 4, 5 or 6, m>1, and m+o=2n+1, R4 and R5 in each case represent H or, together, a methylene group or an additional double bond, R6 represents H, R7 represents OH, OC1-C4-alkyl, OC1-C11-acyl or OSO2NR1R2, the dashed lines in the B and C rings of the steroid skeleton additionally representing up to two double bonds, for the production of a medical drug for the treatment of tumor diseases which can be affected positively by inhibiting the tubulin polymerization. The inventive compounds are distinguished by the 2-alkoxy substitution in conjunction with the 17-hydroxy substitution. They have a special effect with regard to inhibiting tubulin polymerization and can be used, for example, for the treatment of prostate cancers.
    Type: Grant
    Filed: August 13, 2002
    Date of Patent: September 27, 2011
    Assignee: Sterix Limited
    Inventors: Ina Scherlitz-Hofmann, Jens Hoffmann, Alexander Hillisch, Eberhard Unger, Tobias Neumann, Sigfrid Schwarz, Olaf Peters, Thomas Michel
  • Publication number: 20110229551
    Abstract: Polymeric nanofibers have been developed which are useful in a variety of medical and other applications, such as filtration devices, medical prostheses, scaffolds for tissue engineering, wound dressings, controlled drug delivery systems, cosmetic skin masks, and protective clothing. These can be formed of any of a variety of different polymers, both non-biodegradable or biodegradable, and derived from synthetic or natural sources. The present invention discloses 1) the composition of fibrous articles and 2) methods for using these articles in medical applications. The biodegradable fibrous articles, which are preferably formed by electrospinning polymer solution of biodegradable fiberizable material with or in conjunction with medicinal agents and bioactive materials, comprise a composite (or asymmetric composite) of nanofibers with actives.
    Type: Application
    Filed: March 17, 2010
    Publication date: September 22, 2011
    Applicant: NOTUS LABORATORIES, INC.
    Inventors: JAYESH N. DOSHI, LARRY RAYMOND DEBARGE
  • Publication number: 20110229580
    Abstract: Disclosed herein are compositions, methods and kits for a microsphere with one or more entrapped nanoparticles. The method of preparation comprises atomizing a suspension comprising a polysaccharide and one or more nanoparticles into a solution comprising a cross linking agent.
    Type: Application
    Filed: March 22, 2010
    Publication date: September 22, 2011
    Inventors: Rohit SRIVASTAVA, Abhijeet Balwantrao Joshi, R. Keerthi PRASAD
  • Publication number: 20110224723
    Abstract: A tissue adhesive including cyanoacrylate and polyethylene glycol (PEG), wherein the PEG remains a polyether and wherein the tissue adhesive is bioabsorbable. A tissue adhesive including cyanoacrylate bulk monomer and cyanoacrylate nanoparticles containing a therapeutic therein. A kit for applying a tissue adhesive, including the tissue adhesive described above and an applicator. Methods of accelerating degradation of a cyanoacrylate tissue adhesive applying a tissue adhesive, closing an internal wound, administering a therapeutic to tissue, treating cancer, and preventing infection in a wound. Methods of method of making a bioabsorbable tissue adhesive and making a therapeutic tissue adhesive.
    Type: Application
    Filed: November 14, 2007
    Publication date: September 15, 2011
    Inventors: Jeoung Soo Lee, Charles Kenneth Webb, Robert Ziummerman, Rafael Ruiz, SR.
  • Publication number: 20110224176
    Abstract: Provided herein are lyophilized cake forms of fluticasone, salmeterol, or a pharmaceutically acceptable salt or a combination thereof which provides room temperature stability for an extended period of time. Upon reconstitution with an acceptable solvent (e.g., a carrier or diluent), the reconstituted pharmaceutical or cosmetic formulation provides a sterile, non-suspension form suitable for parenteral injectable administration, including subcutaneous injection.
    Type: Application
    Filed: January 14, 2011
    Publication date: September 15, 2011
    Applicant: Lithera, Inc.
    Inventors: John Daniel Dobak, Chris Kemmerer, Kenneth Walter Locke
  • Publication number: 20110212137
    Abstract: An inhalable pharmaceutical solution aerosol comprising beclometasone dipropionate, ethanol and a propellant selected from 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof, wherein the aerosol has a droplet size having a mass median aerodynamic diameter of 0.5-2.0 ?m, for maintaining lung function above 60% of baseline FEV1, or reducing the occurrences of lung function falling below 60% of baseline FEV1.
    Type: Application
    Filed: February 15, 2011
    Publication date: September 1, 2011
    Applicant: TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC.
    Inventors: Paul Michael Dorinsky, David Price
  • Publication number: 20110212053
    Abstract: Provided are compounds according to Formula (I): or stereoisomer, prodrug, polymorph, or pharmaceutically acceptable salt forms thereof, wherein X, Y, R1, R6, R7, and R8 are as defined, and which compounds are effective inhibitors of PI3-kinase and/or other medically and clinically relevant kinases. Also provided are pharmaceutical compositions and methods of using the compounds and compositions as PI3-kinase and kinase inhibitors. More particularly, the compounds of the invention provide treatments and therapeutics for human diseases regulated by, or associated with, the activity of, PI3-kinases and/or protein kinases, or mutant or variant forms thereof.
    Type: Application
    Filed: June 19, 2009
    Publication date: September 1, 2011
    Inventors: Dapeng QIAN, Amy Qi Han, Mark Hamilton, Eric Wang
  • Patent number: 8007831
    Abstract: A process is described for loading hydrophilic polymer particles with a water-insoluble solvent-soluble drug. The particles are preferably embolic agents. The method provides particles having little or no drug at the surface and in a surface layer, whereby the burst effect is minimised. The drug is precipitated in the core of the particle, leading to extended release. The drug is, for instance, paclitaxel, rapamycin, dexamethasone or ibuprofen.
    Type: Grant
    Filed: February 9, 2007
    Date of Patent: August 30, 2011
    Assignee: Biocompatibles UK Limited
    Inventors: Andrew Lennard Lewis, Yiqing Tang, Maria Victoria Gonzalez Fajardo
  • Publication number: 20110206773
    Abstract: Biodegradable polymeric microparticle compositions containing one or more active agents, especially those useful for treating or preventing or one or more diseases or disorders of the eye, and methods of making and using thereof, are described. The microsphere compositions release an effective amount of the one or more active agents for a period greater than 14 days in vivo, preferably greater than 60 days in vivo, more preferably up to 73 days in vivo, more preferably greater than 90 days in vivo, even more preferably over 100 days in vivo, and most preferably greater than 107 days in vivo. In a preferred embodiment, the microparticle compositions contain one or more active agents such as AG1478 to induce nerve regeneration, specifically regeneration of the optic nerve useful for managing elevated intraocular pressure (TOP) in the eye.
    Type: Application
    Filed: November 12, 2010
    Publication date: August 25, 2011
    Inventors: Erin Lavik, James Bertram, Sandeep Saluja, Markus Kuehn, Young H. Kwon, Rebecca Robinson, John J. Huang
  • Patent number: 8003127
    Abstract: Compositions comprising a nanoparticulate corticosteroid and an antihistamine are described. The compositions are useful in the prophylaxis and chronic treatment of asthma in adults and pediatric patients and for the relief of allergic conjunctivitis, symptoms of seasonal allergic rhinitis in adults and pediatric patients. Combining an antihistamine with a nanoparticulate corticosteroid in a single formulation results in improved efficacy.
    Type: Grant
    Filed: March 23, 2006
    Date of Patent: August 23, 2011
    Assignee: Elan Pharma International Limited
    Inventors: Gary Liversidge, Scott Jenkins, H. William Bosch, Christian F. Wertz
  • Publication number: 20110200660
    Abstract: A method of forming a coating on a medical device having a controlled morphology is described. A medical device having a controlled morphology is described.
    Type: Application
    Filed: February 28, 2011
    Publication date: August 18, 2011
    Applicant: Advanced Cardiovascular Systems, Inc.
    Inventors: Lothar Walter Kleiner, Jessica ReneƩ DesNoyer, Stephen Dirk Pacetti, Syed Faiyaz Ahmed Hossainy
  • Publication number: 20110190250
    Abstract: The present invention aims to provide an eye drop for treating macular edema. The present invention provides an eye drop for treating macular edema, which contains difluprednate as an active ingredient. The eye drop can afford effects such as improvement of visual acuity and decreased foveal retinal thickness in macular edema.
    Type: Application
    Filed: July 14, 2010
    Publication date: August 4, 2011
    Inventors: Hidetoshi Yamashita, Teiko Yamamoto, Sakiko Goto, Sachi Abe, Eriko Kirii, Atsushi Okumura
  • Publication number: 20110182994
    Abstract: Methods and systems for preparing nanoparticles. A source of a carrier fluid is connected to an inlet of a flow conduit, such as an intravenous solution administration tube with injection ports, such that the carrier fluid flows through the conduit. A substance (e.g., a drug solution or other substance solution) is introduced into the conduit at a first location causing substance nanoparticles to form within and continue to flow thought he conduit. A stabilizer is introduced into the conduit at a second location to cause a stabilizing effect on the nanoparticles. In some embodiments, the stabilizer may limit or deter agglomeration or growth of the nanoparticles, thereby limiting the size of the nanaparticles produced.
    Type: Application
    Filed: July 27, 2009
    Publication date: July 28, 2011
    Applicants: S.K. PHARMACEUTICALS, INC., THE CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Julia Ann Kornfield, Richard Charles Flagen, Bahar Bingol, John Yol Park
  • Publication number: 20110177169
    Abstract: The eye is effectively treated by providing it with formulations including uncoated cationically charged microparticles of reversed cubic phase or reversed hexagonal phase material. The treatment methods are effective; for a variety of diseases and conditions including dry eye. The structure, charge and components of the microparticles in dispersion, with or without an active ingredient, provide mucoadhesion, layering, protection and prolonged duration of ophthalmic action.
    Type: Application
    Filed: July 9, 2010
    Publication date: July 21, 2011
    Inventors: David Anderson, Vince Conklin, Benjamin Cameransi, David M. Kleinman, Eugene R. Cooper
  • Publication number: 20110165176
    Abstract: Compositions and methods for inducing the deposition of elastin by administering compositions including a mineralocorticoid, such as, for example, aldosterone and, optionally, a secondary active agent for enhancing or modulating the effect of the mineralocorticoid are described herein.
    Type: Application
    Filed: June 8, 2009
    Publication date: July 7, 2011
    Inventors: Aleksander Hinek, Thomas F. Mitts
  • Publication number: 20110165251
    Abstract: The present invention relates to liquid dosage compositions of stable nanoparticulate active agents. The liquid dosage compositions of the invention include osmotically active crystal growth inhibitors that stabilize the nanoparticulate active agents against crystal and particle size growth of the active agent.
    Type: Application
    Filed: March 9, 2011
    Publication date: July 7, 2011
    Inventors: H. William BOSCH, Matthew R. HILBORN, Douglas C. HOVEY, Laura J. KLINE, Robert W. LEE, John D. PRUITT, Niels P. RYDE, Tuula A. RYDE, Shuqian XU
  • Patent number: 7972627
    Abstract: Nasal pharmaceutical formulations comprising a drug substance having a specific particle size distribution profile are disclosed herein. Such profile provides increased bioavailability, increased efficacy or prolonged therapeutic effect of the drug substance when administered intranasally. The formulations of the present invention may comprise one or more corticosteroids having a specific particle size distribution profile. In a preferred embodiment, the corticosteroid is beclomethasone or a pharmaceutically acceptable derivative thereof for the treatment of one or more symptoms of rhinitis. Preferably, the drug substance is beclomethasone dipropionate. The formulations herein may be provided as an aqueous suspension suitable for inhalation via the intranasal route.
    Type: Grant
    Filed: October 14, 2005
    Date of Patent: July 5, 2011
    Assignee: Merck Patent GmbH
    Inventor: Imtiaz Chaudry
  • Publication number: 20110152228
    Abstract: Anhydrous sprayable pharamecutical/dermatological compositions containing, as active pharmaceutical agent, a corticoid, preferably clobetasol propionate, and an oily phase, are formulated in a physiologically acceptable medium, and are useful for the treatment of a variety of conditions and afflictions, notably psoriasis.
    Type: Application
    Filed: March 2, 2011
    Publication date: June 23, 2011
    Applicant: Galderma, S.A.
    Inventors: Nathalie Willcox, Sandrine Orsoni
  • Patent number: 7960368
    Abstract: Described herein are bismethylene-17? carbolactone derivatives having progestational and/or antimineralocorticoid and/or aldosterone antagonistic activity. Also described herein are methods of preparing and using these novel compounds.
    Type: Grant
    Filed: March 4, 2009
    Date of Patent: June 14, 2011
    Assignee: Everstra, Inc.
    Inventors: Klaus Nickisch, Pemmaranu N. Rao, James W. Cessac, Anne Marie Simmons
  • Patent number: 7960367
    Abstract: Steroid compounds processing a hydrogen donor in 3beta position, either in the form of a hydroxy- or a sulfate group, function as efficient blockers of the 3alpha-hydroxy-pregnan-steroid action and thus have utility as therapeutic substances for the prevention and/or treatment of steroid related CNS disorders. Treatment methods based on the administration of these substances are disclosed, and these substances either alone or in combination are also suggested for the manufacture of pharmaceuticals for the treatment of many specific steroid induced CNS disorders.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: June 14, 2011
    Assignee: Umecrine AB
    Inventors: Torbjorn Backstrom, Per Lundgren, Ming-De Wang, Inga-Maj Johansson
  • Publication number: 20110130375
    Abstract: The invention relates to compounds of general formula (I) and pharmaceutically acceptable salts or stereoisomers thereof The compounds are useful for treating diabetic macular edema, diabetic retinopathy, macular degeneration, age-related macular degeneration and other diseases of retina and macula lutea.
    Type: Application
    Filed: July 24, 2009
    Publication date: June 2, 2011
    Applicant: NICOX S.A.
    Inventors: Francesca Benedini, Rebecca Steele, Valerio Chiroli, Stefano Biondi, Ennio Ongini
  • Publication number: 20110130376
    Abstract: The invention relates to compounds of general formula (I) and pharmaceutically acceptable salts or stereoisomers thereof The compounds are useful in the treatment of illnesses wherein the known steroid, parent or precursor steroid, is generally applied, with increased benefit in terms of pharmacological profile and fewer or milder side effects than those of the known steroids.
    Type: Application
    Filed: July 24, 2009
    Publication date: June 2, 2011
    Applicant: NICOX S.A.
    Inventors: Francesca Benedini, Laura Carzaniga, Ennio Ongini, Stefamo Biondi
  • Publication number: 20110123619
    Abstract: A buccal delivery system capable of being blended in a normal dry powder process and compressed using a standard tabletting machine, said buccal delivery system comprising a matrix of: (a) an effective amount of one or more active ingredients; (b) an amount of one or more polyethylene glycols or derivatives thereof having a molecular weight between 1000 to 8000 sufficient to provide the required hardness and time for dissolution of the matrix; (c) 0.05-2% by weight of the total matrix of one or more suspending agents; (d) 0.05-2% by weight of the total matrix of one or more flowing agents; and (e) 0.05-2% by weight of the total matrix of one or more sweeteners.
    Type: Application
    Filed: February 4, 2011
    Publication date: May 26, 2011
    Applicant: OZPHARMA PTY. LTD.
    Inventors: Ernest Alan Hewitt, Richard James Stenlake
  • Patent number: 7947744
    Abstract: Provided herein is a stable pharmaceutical product comprising a dry powder inhalation device, and a pharmaceutical composition that comprises R,R-Formoterol L-tartrate salt, in particular crystalline R,R-formoterol L-tartrate; and ciclesonide.
    Type: Grant
    Filed: January 5, 2006
    Date of Patent: May 24, 2011
    Assignee: Nycomed GmbH
    Inventor: Ruth Margaret Wayland
  • Publication number: 20110117189
    Abstract: New compositions for ophthalmic use for the prevention and therapy of pathologies of the posterior segment of the eye. These compositions utilize xanthan gum as an active principle carrier, and can be advantageously administered as liquid-gel eye drops on the surface of the eye and optionally used in combination with other therapies for the treatment of the same pathologies.
    Type: Application
    Filed: July 8, 2008
    Publication date: May 19, 2011
    Applicant: S.I.F.I. Societa' Industria Farmaceutica Italiana S.P.A.
    Inventors: Maria Grazia Mazzone, Claudine Civiale, Francesco Cuffari
  • Publication number: 20110111006
    Abstract: This invention provides for biocompatible and biodegradable syringeable liquid, implantable solid, and injectable gel pharmaceutical formulations useful for the treatment of systemic and local disease states.
    Type: Application
    Filed: January 14, 2011
    Publication date: May 12, 2011
    Applicant: RAMSCOR, INC.
    Inventors: Vernon G. WONG, Louis L. Wood
  • Publication number: 20110104186
    Abstract: The invention provides immunostimulatory compositions comprising a small molecule immuno-potentiator (SMIP) compound and methods of administration thereof. Also provided are methods of administering a SMIP compound in an effective amount to enhance the immune response of a subject to an antigen. Further provided are novel compositions and methods of administering SMIP compounds alone or in combination with another agent for the treatment of cancer, infectious diseases and/or allergies/asthma. In a further aspect, the invention relates generally to methods of screening for small molecule immuno-modulatory compositions.
    Type: Application
    Filed: June 24, 2005
    Publication date: May 5, 2011
    Inventors: Nicholas Valiante, Feng Xu, Johanna Jansen, Susan Kaufman
  • Publication number: 20110105450
    Abstract: The present invention provides ophthalmic formulations of fluticasone that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic conjunctivitis in a subject in need of such treatment by topical application of the fluticasone formulations of the invention directly to the eye.
    Type: Application
    Filed: June 4, 2010
    Publication date: May 5, 2011
    Applicant: Aciex Therapeutics, Inc.
    Inventors: Matthew J. Chapin, George Minno, Jackie Nice, Paul Gomes, Mark Barry Abelson
  • Publication number: 20110105449
    Abstract: The invention provides dry powder pharmaceutical formulations comprising an ascorbic acid derivative that demonstrate good inhalation performance and dry powder inhalers containing them.
    Type: Application
    Filed: November 6, 2008
    Publication date: May 5, 2011
    Applicant: ASTRAZENECA R&D
    Inventor: Jan Trofast
  • Publication number: 20110097379
    Abstract: The invention is directed to methods of inducing cell recruitment and tissue regeneration at a target site in a subject. It is also based, in part, on the discovery that a subject's own biologic resources and environmental conditions can be used for in situ tissue regeneration and thereby reduce or eliminate the need for donor cell procurement and ex vivo manipulation of such donor cells. Methods are disclosed for recruitment of a subject's own stem cells to a target region by inducing a sustained positive pressure at a target site, such as the kidney, thereby increasing the number of pluripotent cells capable of differentiating to regenerate the target tissue.
    Type: Application
    Filed: May 11, 2009
    Publication date: April 28, 2011
    Inventors: James Yoo, Sang Jin Lee, Mark Van Dyke, Anthony Atala
  • Publication number: 20110098797
    Abstract: The present invention relates to materials having therapeutic compositions releasably contained within the materials. The materials are configured to release therapeutic compositions at a desired rate. The present invention also relates to devices incorporating the materials.
    Type: Application
    Filed: October 21, 2010
    Publication date: April 28, 2011
    Inventors: Robert L. Cleek, Edward H. Cully, Theresa A. Holland
  • Publication number: 20110098640
    Abstract: The present disclosure relates to methods for visualizing the opening of a drug reservoir of an implantable medical device. In particular, the present disclosure provides methods for observing the release or exposure of contents from a drug reservoir of a medical device placed within the vitreous of an eye of a subject. The methods include implanting a drug delivery device within an anatomy of a subject. The drug device includes a plurality of reservoirs, each loaded with a therapeutic agent and a marker. Furthermore, the drug delivery device comprises a plurality of barrier layers for separating the contents of one of the plurality of reservoirs from the anatomy. The method further includes irradiating at least one of the plurality of barrier layers such that at least one of the plurality of reservoirs is breached, thereby triggering release of the therapeutic agent and the marker from the device.
    Type: Application
    Filed: October 22, 2010
    Publication date: April 28, 2011
    Inventors: Kenneth N. HORNE, Gregory J.R. Spooner, John A. Scholl, John T. Santini, JR.
  • Patent number: 7927621
    Abstract: A poly(thioester ester amide) copolymer and method of making and using the same are disclosed.
    Type: Grant
    Filed: June 25, 2007
    Date of Patent: April 19, 2011
    Assignee: Abbott Cardiovascular Systems Inc.
    Inventors: Mikael O. Trollsas, Nam D. Pham, Michael H. Ngo, Bozena Zofia Maslanka
  • Publication number: 20110086100
    Abstract: A polyethylene glycol (PEG) aerogel particles having an average particle diameter not substantially above about 2?, a volumetric porosity of greater than about 50%, and pore sizes capable of retaining drug molecules. A method for preparing such polyethylene glycol (PEG) aerogel particles includes initiating a catalyzed reaction using a catalyst of PEG forming ingredients to form PEG particles; partially drying the formed PEG particles under conditions to control pore size; and subjecting the partially dried formed PEG particles to CO2 supercritical extraction for form the PEG aerogel particles. Drug molecules include chemotherapeutic agents. The surface of the PEG aerogel particles are reactable with a variety of agents, for example, to selectively target tumors, protects irreversible damage to labile proteins, and protects degradation of sensitive drugs with subsequent loss of biological efficacy.
    Type: Application
    Filed: October 12, 2010
    Publication date: April 14, 2011
    Inventor: Yosry A. Attia
  • Publication number: 20110081411
    Abstract: The present invention is directed to orally administered corticosteroid compositions. The present invention also provides a method for treating a condition associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention.
    Type: Application
    Filed: October 1, 2010
    Publication date: April 7, 2011
    Inventors: Stephen Perrett, Fredric Jay Cohen, Gopi Venkatesh
  • Publication number: 20110077229
    Abstract: Pharmaceutical composition for intraocular use comprising a glucocorticoid derivative, such as beclomethasone 17,21-diproprionate admixed with a biodegradable polymer such as a poly(lactide-co-glycolide) polymer or a high molecular weight polymeric hyaluronic acid are disclosed.
    Type: Application
    Filed: December 6, 2010
    Publication date: March 31, 2011
    Inventors: Jeffrey L. Edelman, Kelly M. Harrison, Patrick M. Hughes, Lon T. Spada